Please check your internet connection and try again.
# Montelukast/Levocetirizine
## Overview
A fixed-dose combination (FDC) of montelukast (a leukotriene receptor antagonist) and levocetirizine (a second-generation antihistamine). This combination provides dual-pathway inhibition for allergic conditions.
## Primary Indications
* Allergic rhinitis (perennial and seasonal).
* Chronic urticaria.
* Off-label: Adjunctive therapy for asthma with allergic rhinitis.
## Adult Dosing
* **Standard dose:** 1 tablet daily (containing 10 mg montelukast and 5 mg levocetirizine).
* **Timing:** Administer in the evening.
## Pediatric Dosing
* **Children 6–14 years:** Generally 1 tablet daily (containing 5 mg montelukast and 2.5 mg levocetirizine).
* **Children <6 years:** Not typically recommended as a fixed-dose combination due to weight-based titration requirements.
* *Note:* Dose may vary based on regional availability of specific FDC products. Consult local pediatric protocols.
## Dose Adjustments
* **Renal Impairment:** Levocetirizine requires dosage reduction in chronic kidney disease (CrCl <50 mL/min). If using FDC, dosage must be modified or components separated to allow levocetirizine dose reduction.
* **Hepatic Impairment:** Montelukast requires no specific adjustment; monitor for levocetirizine clearance if severe impairment exists.
## Contraindications
* Hypersensitivity to montelukast, levocetirizine, or cetirizine.
* Severe renal impairment (CrCl <10 mL/min) or patients undergoing hemodialysis, unless using adjusted, separate components.
## Adverse Effects
* **Montelukast:** Neuropsychiatric events (agitation, depression, sleep disturbances, suicidal ideation), headache, increased hepatic enzymes.
* **Levocetirizine:** Somnolence, fatigue, nasopharyngitis, dry mouth.
## Key Drug Interactions
* **CNS Depressants:** Levocetirizine may potentiate the effects of alcohol or other CNS depressants.
* **CYP450 Inducers:** Phenobarbital, phenytoin, or rifampin may decrease montelukast plasma levels.
* *Note:* Clinically significant interactions with the FDC are generally low, but additive sedation is the primary concern.
## Monitoring
* **Neuropsychiatric:** Monitor for mood, behavior, or sleep changes, particularly with montelukast.
* **Renal Function:** Periodic assessment of CrCl if long-term use is intended in patients with pre-existing renal issues.
* **Efficacy:** Symptom resolution or improvement in allergic rhinitis/urticaria scores.
## Clinical Pearls
* **Black Box Warning:** The FDA recommends reserving montelukast for patients who do not respond to or cannot tolerate alternative therapies due to the risk of serious neuropsychiatric events.
* **Patient Education:** Advise patients to monitor for mood changes or irritability. Use caution when operating heavy machinery until individual sedative effects of levocetirizine are known.
* **Administration:** Evening administration is preferred to cover nocturnal symptoms and mitigate daytime sedation from the antihistamine component.
***
**Educational Disclaimer:** This information is for educational purposes only. Prescribing information, local clinical protocols, and product availability may vary by region. Always verify specific dosing, safety warnings, and contraindications via current institutional guidelines or official package inserts before prescribing or dispensing.
